Chemical and Pharmaceutical Bulletin
Online ISSN : 1347-5223
Print ISSN : 0009-2363
ISSN-L : 0009-2363
Regular Articles
Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders
Satoshi Mikami , Masanori Kawasaki, Shuhei Ikeda, Nobuyuki Negoro, Shinji Nakamura, Izumi Nomura, Tomoko Ashizawa, Hironori Kokubo, Isaac Dylan Hoffman, Hua Zou, Hideyuki Oki, Noriko Uchiyama, Yuuto Hiura, Maki Miyamoto, Yuuki Itou, Masato Nakashima, Hiroki Iwashita, Takahiko Taniguchi
Author information
Keywords: phospodiesterase 2A, schizophrenia, pyrazolo[1,5-a]pyrimidine, structure-based drug design, phototoxicity, intramolecular hydrogen bond
JOURNAL FREE ACCESS FULL-TEXT HTML
Supplementary material

2017 Volume 65 Issue 11 Pages 1058-1077

Details
Full-text HTML Download PDF (2248K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

It has been hypothesized that selective inhibition of phosphodiesterase (PDE) 2A could potentially be a novel approach to treat cognitive impairment in neuropsychiatric and neurodegenerative disorders through augmentation of cyclic nucleotide signaling pathways in brain regions associated with learning and memory. Following our earlier work, this article describes a drug design strategy for a new series of lead compounds structurally distinct from our clinical candidate 2 (TAK-915), and subsequent medicinal chemistry efforts to optimize potency, selectivity over other PDE families, and other preclinical properties including in vitro phototoxicity and in vivo rat plasma clearance. These efforts resulted in the discovery of N-((1S)-2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (20), which robustly increased 3′,5′-cyclic guanosine monophosphate (cGMP) levels in the rat brain following an oral dose, and moreover, attenuated MK-801-induced episodic memory deficits in a passive avoidance task in rats. These data provide further support to the potential therapeutic utility of PDE2A inhibitors in enhancing cognitive performance.

Graphical Abstract Fullsize Image
Content from these authors
© 2017 The Pharmaceutical Society of Japan
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top